ImmunoPrecise recently announced important changes to its Board of Directors and upcoming financial reporting activities. At its recent Annual General Meeting, the company welcomed Mitch Levine to its Board of Directors, which was followed soon thereafter by his appointment as the Chairman of the Board. With extensive experience in the life sciences industry and in financial strategy, specifically in Nasdaq market operations, Levine brings valuable expertise to the company. Levine has been the CEO and Chairman of SmartHealth Dx since 2022.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IPA:
- ImmunoPrecise Antibodies 1.1M share Spot Secondary priced at $1.00
- ImmunoPrecise Antibodies announces common stock offering
- ImmunoPrecise Antibodies announce board and committee chair appointments
- ImmunoPrecise’s BioStrand launches RAG-based LLM platform
- ImmunoPrecise Antibodies provides update on recent share movement
